Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 159 B, Issue 7, 2012, Pages 874-883

  Bekris, Lynn M ^a,b   Millard, Steve ^a   Lutz, Franziska ^a,b   Li, Gail ^c   Galasko, Doug R ^d   Farlow, Martin R ^e   Quinn, Joseph F ^f,g   Kaye, Jeffrey A ^f,g   Leverenz, James B ^a,c,h   Tsuang, Debby W ^a,c   Yu, Chang En ^a,b   Peskind, Elaine R ^a,c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g PORTLAND VA MEDICAL CENTER   (United States)

^h Veterans Administration Northwest Network   (United States)

Author keywords

AD; CSF; FYN; MAPT; PPP2R4

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GAK PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; PEPTIDYLPROLYL ISOMERASE PIN1; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE; PPP2R4 PROTEIN; PPP3R1 PROTEIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE FYN; TAU PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TAU PROTEINS;

EID: 84866328064     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32094     Document Type: Article

References (40)

1. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J. 2006. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9(3):293-348.
2. Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M, Machida N, Lee VM, Trojanowski JQ, Sasaki H. 1997. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 236(2):262-264.
3. Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Tsuang D, Peskind ER, Yu CE. 2008. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis 13(3):255-266.
4. Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239-259.
5. Chin J, Palop JJ, Puolivali J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. 2005. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25(42):9694-9703.
6. Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, Mucke L. 2004. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 24(19):4692-4697.
7. Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, Leverenz JB, Galasko D, Morris JC, Fagan AM, Holtzman DM, Goate AM. 2010. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 6(9):pii: e1001101.
8. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. 2006. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59(3):512-519.
9. Hanger DP, Anderton BH, Noble W. 2009. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 15(3):112-119.
10. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. 2001. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297(3):187-190.
11. Ho GJ, Hashimoto M, Adame A, Izu M, Alford MF, Thal LJ, Hansen LA, Masliah E. 2005. Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: Implications for its functional role. Neurobiol Aging 26(5):625-635.
12. Holm S. 1979. A simple sequential rejective multiple test procedure. Scand J Stat 6:65-70.
13. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. 2009. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118(1):53-69.
14. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Buerger K, Wiltfang J, Otto M, Kretzschmar H, Moeller HJ, Imagawa M, Kohno H, Nakashima K, Kuzuhara S, Sasaki H, Imahori K. 2001. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 50(2):150-156.
15. Ittner LM, Gotz J. 2011. Amyloid-beta and tau-A toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12(2):65-72.
16. Lebouvier T, Scales TM, Williamson R, Noble W, Duyckaerts C, Hanger DP, Reynolds CH, Anderton BH, Derkinderen P. 2009. The microtubule-associated protein tau is also phosphorylated on tyrosine. J Alzheimers Dis 18(1):1-9.
17. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J. 2004. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: Original data and review of the literature. J Mol Neurosci 23(1-2):115-122.
18. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. 2005. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22(8):1942-1950.
19. Martin L, Latypova X, Terro F. 2011. Post-translational modifications of tau protein: Implications for Alzheimer's disease. Neurochem Int 58(4):458-471.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7):939-944.
21. Pastor IJ, Laso FJ, Ines S, Marcos M, Gonzalez-Sarmiento R. 2009. Genetic association between -93A/G polymorphism in the Fyn kinase gene and alcohol dependence in Spanish men. Eur Psychiatry 24(3):191-194.
22. Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR. 2006. Age and apolipoprotein E 4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 63(7):936-939.
23. Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, Raskind MA, Galasko D. 2005. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 19(4):220-225.
24. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. 1999. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56(3):303-308.
25. Price JL, Morris JC. 1999. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45(3):358-368.
26. Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F. 2010. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 19(4):1221-1229.
27. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L. 2011. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31(2):700-711.
28. Rosenbloom KR, Dreszer TR, Pheasant M, Barber GP, Meyer LR, Pohl A, Raney BJ, Wang T, Hinrichs AS, Zweig AS, Fujita PA, Learned K, Rhead B, Smith KE, Kuhn RM, Karolchik D, Haussler D, Kent WJ. 2010. ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res 38(Database issue):D620-D625.
29. Rybakowski JK, Borkowska A, Skibinska M, Hauser J. 2007. Polymorphisms of the Fyn kinase gene and a performance on the Wisconsin Card Sorting Test in schizophrenia. Psychiatr Genet 17(3):201-204.
30. Sato-Harada R, Okabe S, Umeyama T, Kanai Y, Hirokawa N. 1996. Microtubule-associated proteins regulate microtubule function as the track for intracellular membrane organelle transports. Cell Struct Funct 21(5):283-295.
31. Schumann G, Rujescu D, Kissling C, Soyka M, Dahmen N, Preuss UW, Wieman S, Depner M, Wellek S, Lascorz J, Bondy B, Giegling I, Anghelescu I, Cowen MS, Poustka A, Spanagel R, Mann K, Henn FA, Szegedi A. 2003. Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts. Biol Psychiatry 54(12):1422-1426.
32. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ. 2009. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65(4):403-413.
33. Shirazi SK, Wood JG. 1993. The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. Neuroreport 4(4):435-437.
34. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. 2009. Tau pathophysiology in neurodegeneration: A tangled issue. Trends Neurosci 32(3):150-159.
35. Szczepankiewicz A, Breborowicz A, Skibinska M, Wilkosc M, Tomaszewska M, Hauser J. 2008. Association analysis of tyrosine kinase FYN gene polymorphisms in asthmatic children. Int Arch Allergy Immunol 145(1):43-47.
36. Usardi A, Pooler AM, Seereeram A, Reynolds CH, Derkinderen P, Anderton B, Hanger DP, Noble W, Williamson R. 2011. Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS J 278(16):2927-2937.
37. van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YA, van der Flier WM, Scheltens P. 2011. Tau and p-tau as CSF biomarkers in dementia: A meta-analysis. Clin Chem Lab Med 49(3):353-366.
38. Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. 2012. Abnormal hyperphosphorylation of tau: Sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis [Epub ahead of print].
39. Watanabe T, Ohnuma T, Shibata N, Ohtsuka M, Ueki A, Nagao M, Arai H. 2004. No genetic association between Fyn kinase gene polymorphisms (-93A/G, IVS10+37T/C and Ex12+894T/G) and Japanese sporadic Alzheimer's disease. Neurosci Lett 360(1-2):109-111.
40. Yang K, Belrose J, Trepanier CH, Lei G, Jackson MF, MacDonald JF. 2011. Fyn, a potential target for Alzheimer's disease. J Alzheimers Dis 27(2):243-252.